On December 17, Changfeng Pharmaceutical (02652) announced that its clinical trial application for the self-developed fixed-dose compound preparation olopatadine mometasone nasal spray has been accepted by the National Medical Products Administration (NMPA) of China.

The application, numbered CYHL2500215/CYHL2500214, is for the treatment of moderate to severe allergic rhinitis symptoms in adults and adolescents aged 12 years and older. The acceptance of this clinical trial application signifies that the product has officially entered the NMPA's regulatory review stage for potential clinical development.

This product combines antihistamines and corticosteroids, aiming to provide a convenient treatment option for patients whose symptoms are not effectively controlled. The company believes that if the product is successfully developed and approved, it will enhance its allergy and rhinitis product line and may complement its existing product portfolio.

The company will continue to communicate with the NMPA, comply with relevant laws and regulations, and advance subsequent clinical development activities. The announcement also cautions that the drug development process involves significant uncertainties, and there is no guarantee that a clinical trial application will lead to successful commercialization. Shareholders and potential investors should exercise caution and mitigate investment risks.

https://finance.eastmoney.com/a/202512173594492058.html